The p53 tumor suppressor pathway is dysfunctional in some colorectal cancers [3], and to this end, identification of therapeutics that is capable of specifically re-activating p53-mediated apoptosis affords a tempting approach to treat colon cancer. This evidence concerns the gene TP53 and colorectal cancer.